MRKC Stock Overview
Operates as a science and technology company in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for MRKC from our risk checks.
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €28.20 |
| 52 Week High | €34.60 |
| 52 Week Low | €26.60 |
| Beta | 0.71 |
| 11 Month Change | -13.50% |
| 3 Month Change | -16.07% |
| 1 Year Change | -9.03% |
| 33 Year Change | -35.91% |
| 5 Year Change | n/a |
| Change since IPO | 5.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRKC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.4% | -10.1% | -1.5% |
| 1Y | -9.0% | -21.6% | 7.9% |
Return vs Industry: MRKC exceeded the German Pharmaceuticals industry which returned -24.1% over the past year.
Return vs Market: MRKC underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| MRKC volatility | |
|---|---|
| MRKC Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MRKC has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MRKC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 62,255 | Belen Garijo Lopez | www.merckgroup.com/en |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
| MRKC fundamental statistics | |
|---|---|
| Market cap | €60.87b |
| Earnings (TTM) | €2.70b |
| Revenue (TTM) | €20.96b |
22.6x
P/E Ratio2.9x
P/S RatioIs MRKC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRKC income statement (TTM) | |
|---|---|
| Revenue | €20.96b |
| Cost of Revenue | €8.64b |
| Gross Profit | €12.33b |
| Other Expenses | €9.63b |
| Earnings | €2.70b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 06, 2025
| Earnings per share (EPS) | 6.20 |
| Gross Margin | 58.80% |
| Net Profit Margin | 12.86% |
| Debt/Equity Ratio | 37.8% |
How did MRKC perform over the long term?
See historical performance and comparison